Company: DVAX
Filing Date: 2025-05-16
Form Type: DFAN14A
Source: 0001193125-25-121025
Chunk: 3

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-16
Form: DFAN14A
Chunk 3
---
                                       
 Objective, investor-aligned perspectives are needed to ensure that shareholders’ interests are once again prioritized when evaluating capital allocation and strategic decisions.                                                                                                                                                                |

| • |     | Deep Track’s director candidates would bring valuable experience, independence and investor perspective 
 to the Dynavax Board.                                                                                   |

| • |     | Brett Erkman brings a long-term shareholder perspective on capital allocation, investor communications, 
 capital markets and best practices of other publicly traded biotechnology companies.                    |

| • |     | Jeffrey Farrow brings experience in biopharma finance, a functional expertise in evaluating optimal                                                                                       
 capital allocation, is a qualified audit expert, and has a deep understanding of the regulatory environment in the pharmaceutical industry and knowledge of the drug development process. |

| • |     | Donald Santel brings prior CEO experience from two public companies, prior board leadership experience, 
 and a demonstrated independent approach to advocating for shareholders’ best interests.                 |

| • |     | Michael Mullette brings highly relevant industry experience derived from overseeing commercialization of                                                                                                                                          
 the Moderna COVID-19 vaccine (one of the most successful vaccine launches in history), as well as a deep understanding of the biotechnology business risks and extensive day-to-day operational experience from his nearly two decades at Sanofi. |

3

We are deeply concerned that the Dynavax Board is leading the Company down a path of value destruction. If
elected, Deep Track’s nominees are prepared to critically evaluate the Company’s strategy and help ensure it is on the best trajectory for all stakeholders, while working collaboratively with the rest of the Board in pursuit of this goal.
We encourage you to make your voice heard at the upcoming Annual Meeting by voting for meaningful, shareholder-driven change.

For more information,
including details on how to vote Deep Track’s proxy card, please visit .

Regards,

David Kroin

Founder and Chief Investment Officer, Deep Track
Capital LP

EVERY VOTE MATTERS

Your vote is important, no matter how many shares of Common Stock you own.

If you have any questions, require assistance in voting your proxy card, or need additional copies

of Deep Track’s proxy materials, please visit or contact our proxy solicitor,

Innisfree M&A Incorporated (“Innisfree”), using the contact information provided here:

Innisfree M&A Incorporated

501 Madison Avenue, 20 Floor

New York, New York 10022

Stockholders call toll-free (877) 687-1865

About Deep Track Capital

Deep Track Capital is a